Ecosystem Contributor - Coming Soon -

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

LOGO CONTEST Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Register Rules for the logo contest Design must be based on “Alebrijes” [ah-leh-bree-hez], which are chimeric creatures from Mexican folklore AND contain adhesion GPCRs Avoid copyrighted material unless a CC BY / open-use license has been acquired or generated (Adobe Stock, etc). The Consortium must be free to use the design. Requirements: Resolution 300 ppi max, JPEG/TIFF/EPS/PNG/PDF formats, 5MB max Open to all adhesion GPCR community members. Artist-scientists must be registered to attend the adhesion GPCR workshop 2024 in Mexico City. The contest deadline is August 15th, 2024, 11:59 PM CST (designs received after the deadline will not be considered) Designs or inquiries should be sent to this email The prize for the selected design will include free registration and more! Register for the Adhesion GPCR 2024 Learn more about the Adhesion GPCR workshop 2024 Up About the event Learn more about the Adhesion GPCR workshop 2024 and its preliminary program. Up About the venue Discover Cinvestav, the host venue for the upcoming workshop. Up Abstract Submission Submit your research abstracts following our guidelines to present at the conference. Up Traveling Tips Find essential tips about Mexico City, including transportation options and local insights.

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

22nd GPCR Retreat

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Dr. GPCR Podcast << Back to podcast list Dr. Fiona Marshall About this episode Fiona Marshall got fascinated with GPCRs after attending a lecture on how the beta-adrenergic receptor in the heart is activated by adrenaline, during her undergraduate studies at Bath University. She then pursued her Ph.D. in neuroscience at Cambridge University. An expert in GPCR biology, Fiona published the first description of the cloning and structural requirements of the GABAB receptor. One of her career path-defining moments came when she visited Dr. Chris Tate and Dr. Richard Henderson at the Laboratory of Molecular Biology in Cambridge, UK. As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery and development biotechnology company, Fiona and her team made considerable breakthroughs in the field of GPCR stabilization and structure-based drug design. Today, Dr. Marshall is the VP Head of Neuroscience Discovery and Head of Discovery UK, Global Head of Neuroscience discovery research leading teams in West Point, Boston, and London at MSD. Join me and learn more about her fascinating career trajectory. Dr. Fiona Marshall on the web LinkedIn Twitter Google Scholar MSD UK Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Dr. GPCR Podcast << Back to podcast list Dr. Stuart Maudsley About Dr. Stuart Maudsley Stuart graduated from the University of Leeds in the U.K. with a First Class Honors degree in Pharmacology. At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. He then completed his Ph.D. at Leeds as well as the University’s Ackroyd, Brotherton, and Brown Scholar. Following his Ph.D., Dr. Maudsley was awarded a Howard Hughes Medical Institute Fellowship to train with Professor Robert Lefkowitz at Duke University. Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor Biology Section at the Medical Research Council (MRC) -Human Reproductive Sciences Unit within the University of Edinburgh. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional signaling. To broaden his biomedical skill-set Stuart next accepted the position of Head of the Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns Hopkins University Medical Center. At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award, one of the few awards available within the intramural NIH program. Upon starting a new family, and returning to Europe, Dr. Maudsley continued his scientific journey with the award of the highly-valued Odysseus Program Type I Program Grant to work as both the Adjunct Director of the VIB Center for Molecular Neurology and also Vice-Chair of the Department of Biomedical Sciences at the University of Antwerp. Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases based on their gerontological underpinnings. This research stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles. Dr. Stuart Maudsley on the web Maudsley Lab LinkedIn Google Scholar ResearchGate Maudsley Lab on Facebook Receptor Biology Lab Facebook Group Twitter Semantic Scholar Instagram Neurotree Dimensions Reddit Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

< GPCR News < GPCRs in Oncology and Immunology A virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P1 signaling axis Published date August 15, 2023 ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers GPCR Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology Structural and molecular insights into GPCR function GPCR Activation and Signaling More from Dr. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr. GPCR Monthly Newsletter today! Follow the Dr. GPCR News and get weekly notifications about the GPCR field Share < Previous Next >

Dr. GPCR Podcast << Back to podcast list Dr. Richard Premont About Dr. Richard Premont "Dr. Premont obtained his B.S. in Biology and Chemistry at the California Institute of Technology in 1985, and M.Ph . and Ph.D. in Biomedical Sciences (Pharmacology) at Mount Sinai School of Medicine (City University of New York) in 1990 and 1992, working with Ravi Iyengar on regulation/desensitization of the liver glucagon receptor and glucagon-stimulated adenylyl cyclase system. In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert Lefkowitz and Marc Caron at Duke University. His initial project to identify and clone taste receptors was unsuccessful, but led to the identification of GRK5 and continued focus on GRKs (particularly GRKs 4,5,6) and arrestins as GPCR regulators and as mediators of distinct signaling pathways through partners including GIT1. In 1999, obtained an independent faculty position at Duke in Gastroenterology, where he remained until 2018 studying GPCRs and their signaling pathways in the liver and in liver disease. In 2018, he moved to Harrington Discovery Institute and Case Western Reserve University, where he studies GPCR regulation by S-nitrosylation. My research focus is on understanding how distinct cellular signaling pathways interact and are coordinated to produce integrated physiological responses, and how dysregulation of this coordination results in pathophysiology. For this, we have worked in three main areas: the regulation of G protein-coupled receptor signaling particularly by the G protein-coupled receptor kinase (GRK) – beta-arrestin system, the coordination of heterotrimeric G protein, small GTP-binding protein and protein kinase pathways by GIT/PIX scaffolding complexes during cellular signaling, and characterizing the role of protein S-nitrosylation as a signaling post-translational modification in mediating and regulating cellular signaling pathways, particularly in conjunction with better characterized signaling systems. In our work, we utilize methods including structural biology and proteomics, molecular biology and biochemical enzymology, primary and model cell culture, and transgenic, knockout, knock-in and conditional models of mouse physiology and behavior." Dr. Richard Premont on the web Google Scholar LinkedIn Dr. GPCR Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

< GPCR News < GPCRs in Oncology and Immunology Delivery of US28 by incoming HCMV particles rapidly attenuates Akt activity to suppress HCMV lytic replication in monocytes Published date August 27, 2024 Abstract "Establishing a nonproductive, quiescent infection within monocytes is essential for the spread of human cytomegalovirus (HCMV). We investigated the mechanisms through which HCMV establishes a quiescent infection in monocytes. US28 is a virally encoded G protein-coupled receptor (GPCR) that is essential for silent infections within cells of the myeloid lineage. We found that preformed US28 was rapidly delivered to monocytes by HCMV viral particles, whereas the de novo synthesis of US28 was delayed for several days. A recombinant mutant virus lacking US28 (US28Δ) was unable to establish a quiescent infection, resulting in a fully productive lytic infection able to produce progeny virus. Infection with US28Δ HCMV resulted in the phosphorylation of the serine and threonine kinase Akt at Ser473 and Thr308, in contrast with the phosphorylation of Akt only at Ser473 after WT viral infection. Inhibiting the dual phosphorylation of Akt prevented the lytic replication of US28Δ, and ectopic expression of a constitutively phosphorylated Akt variant triggered lytic replication of wild-type HCMV. Mechanistically, we found that US28 was necessary and sufficient to attenuate epidermal growth factor receptor (EGFR) signaling induced during the entry of WT virus, which led to the site-specific phosphorylation of Akt at Ser473. Thus, particle-delivered US28 fine-tunes Akt activity by limiting HCMV-induced EGFR activation during viral entry, enabling quiescent infection in monocytes." Authors Jamil Mahmud, Brittany W Geiler, Juthi Biswas, Michael J Miller, Julia E Myers, Stephen M Matthews, Amanda B Wass, Christine M O'Connor, Gary C Chan Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers GPCR Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology Structural and molecular insights into GPCR function GPCR Activation and Signaling More from Dr. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr. GPCR Monthly Newsletter today! Follow the Dr. GPCR News and get weekly notifications about the GPCR field Share < Previous Next >

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Removing the GPCR-mediated brake on exocytosis enhances insulin action, promotes adipocyte browning, and protects against diet-induced obesity Date & Time Friday, November 3rd / 2:45 PM Abstract Coming Soon Authors and Affiliations Ryan P. Ceddia 1, *, Zack Zurawski 2,3,*, Analisa Thompson Gray 2, Feyisayo Adegboye 2, Ainsley McDonald-Boyer 3, Fubiao Shi 1, Dianxin Liu 1, Jose Maldonado 5, Jiesi Feng 4, Yulong Li 4, Simon Alford 5, Julio E. Ayala 5, Owen P. McGuinness 5, Sheila Collins 1,5, Heidi E. Hamm 2 1 Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA 2 Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA 3, 5 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232, USA 4 Peking University, China 5 Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612, USA. About Heidi Hamm "Heidi E. Hamm, Ph.D. is the Aileen M. Lange and Annie Mary Lyle Chair in Cardiovascular Research, and Professor of Pharmacology, Ophthalmology and Visual Sciences, and Orthopedics at Vanderbilt University. This is one of the top Pharmacology departments in the country, judged by reputation, citation analysis, and NIH funding. She oversaw an increase of the size of the Department, as well as a quintupling of its NIH funding, in her 14 years as Chair. The Department’s strengths lie in GPCR signal transduction and neuroscience, and she has expanded it in the areas of drug discovery and structural biology of membrane proteins. Her research focuses on the structure and function of GTP binding proteins and the molecular mechanisms of signal transduction. Her laboratory has been involved in studying G protein coupled signal transduction for many years and has made key discoveries in G protein structure and mechanisms of activation by GPCRs and activation of effectors. Current areas of interest include Protease Activated Receptor signaling in the cardiovascular system and regulation of vesicular exocytosis mediated by Gi/o-coupled receptors by G subunit binding to SNAREs. Dr. Hamm obtained her Ph.D. in 1980 from the Department of Zoology at the University of Texas-Austin and did postdoctoral training in the University of Wisconsin-Madison from 1980-1983. Her initial research centered around circadian clocks and melatonin synthesis in the avian retina; her postdoctoral work investigated the role of the G protein transducin in visual transduction using blocking monoclonal antibodies. She held faculty appointments at the University of Illinois at Chicago School of Medicine and Northwestern University before moving to Vanderbilt in 2000. She has received numerous awards, including the Glaxo Cardiovascular Discovery Award, the Distinguished Investigator Award from the National Alliance for Research in Schizophrenia and Depression, the Faculty of the Year award from the University of Illinois College of Medicine, and the Stanley Cohen Award “For Research Bringing Diverse Disciplines, such as Chemistry or Physics, to Solving Biology’s Most Important Fundamental Problems” from Vanderbilt University in 2003. She gave the Fritz Lipmann Lecture at ASBMB in 2001. " Heidi Hamm on the web The Hamm Lab Vanderbilt School of Medicine Pubmed Google Scholar LinkedIn Twitter Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Dr. GPCR Podcast << Back to podcast list Dr. Caron Tribute Part 2 ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure to animal models of disease Date & Time Friday, November 3rd / 11:05 AM Abstract Coming Soon About Patrick Sexton " Patrick Sexton is a NHMRC Senior Principal Research Fellow and Director, ARC Centre for Cryo-electron Microscopy of Membrane Proteins ( www.ccemmp.org ). He is a leader in the study of GPCRs. Recently, his team has applied cryo-EM to elucidation of the structure and dynamics of GPCRs. Prof. Sexton has published over 335 peer reviewed journal articles and has been cited >29,000 times (Google Scholar). He is a 2022 Clarivate Analytics Highly Cited Researcher in two disciplines: Pharmacology & Toxicology; Biology & Biochemistry, a corresponding member of NC-IUPHAR, a member of the Faculty of 1000 and an elected Fellow of the British Pharmacological Society (BPS). Prof. Sexton’s awards include the ASCEPT Lecturer award, Endocrine Society (Australia) Senior Plenary award, Rand Medal (ASCEPT), Paxinos-Watson Award (Australian Neuroscience Society), Vane Medal (BPS), Gordon Hammes Lectureship Award (American Chemical Society) and the GSK Research Excellence award. Prof. Sexton is also a co-founder of Septerna Inc. " Patrick Sexton on the web CCeMMP Monash University Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways Date & Time Thursday, November 2nd / 4:30 PM Keynote Talk Abstract Coming Soon About Kathleen Caron "Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department consistently ranked in the Top 5 in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health." Kathleen Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer Center Twitter Google Scholar ORCID ResearchGate Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back